⦁ Theme Tracker

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Energy & Environment Ⓛ Solar Politics & Policy

Congress Could Soon Approve Billions of Dollars to Continue Developing US Solar Capacity, Production

The Inflation Reduction Act's provisions regarding renewable energy incentives are worth hundreds of billions of dollars. Perhaps the most critical…

McAlinden Research PartnersAugust 2, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Politics & Policy

COVID Vaccines Continue to Drive Significant Pharma Revenues as BA.5 Variant Cases on the Rise

Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…

McAlinden Research PartnersAugust 1, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Ⓛ Aerospace & Defense Manufacturing & Logistics Politics & Policy

US Deploys More HIMARS to Ukraine, But Replenishing Stockpiles at Home Increasingly Critical

The Biden Administration is prepping the US's latest wave of military assistance to Ukraine in their defensive struggle against the Russian invasion.…

McAlinden Research PartnersJuly 26, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Ⓛ Cybersecurity Markets Technology

Cyberthreats Resistant to Economic Headwinds, Cybersecurity Spending Will Have to Keep Up

The number of cyberattacks are on the rise, but the average cost of each attack is increasing even faster. Billions of…

McAlinden Research PartnersJuly 22, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines

Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…

McAlinden Research PartnersJuly 14, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Markets

CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years

A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…

McAlinden Research PartnersJuly 11, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Economics & Trade Ⓛ Travel & Leisure Services

Cruise Lines Push Capacity to Counter High Energy Costs, Heavy Debt Loads Loom Large

Shares of major cruise lines have been hit hard by a broader weakening of economic growth and rising energy costs.…

McAlinden Research PartnersJuly 6, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Commodities Energy & Environment Ⓛ Uranium Politics & Policy

Nuclear Power Revival Reaches Across Europe and Asia, Remaining Holdouts Could Suffer Energy Shortages

Nuclear power is back on the rise across much of Europe and Asia. Earlier this year, France led a coalition…

McAlinden Research PartnersJuly 5, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Economics & Trade Finance Ⓛ Aerospace & Defense Manufacturing & Logistics Politics & Policy

US Set to Boost Military Presence in Europe and Push Defense Budget to New Highs

With Finland and Sweden now set to join NATO in the near future, tensions between the organization's member states and Russia…

McAlinden Research PartnersJune 30, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Big Pharma Set to Let Biotech Bleed Continue Before Deploying Massive Cash Balances

Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…

McAlinden Research PartnersJune 14, 2022

Congress Could Soon Approve Billions of Dollars to Continue Developing US Solar Capacity, Production

COVID Vaccines Continue to Drive Significant Pharma Revenues as BA.5 Variant Cases on the Rise

US Deploys More HIMARS to Ukraine, But Replenishing Stockpiles at Home Increasingly Critical

Cyberthreats Resistant to Economic Headwinds, Cybersecurity Spending Will Have to Keep Up

Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines

CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years

Cruise Lines Push Capacity to Counter High Energy Costs, Heavy Debt Loads Loom Large

Nuclear Power Revival Reaches Across Europe and Asia, Remaining Holdouts Could Suffer Energy Shortages

US Set to Boost Military Presence in Europe and Push Defense Budget to New Highs

Big Pharma Set to Let Biotech Bleed Continue Before Deploying Massive Cash Balances

Joe Mac’s Viewpoint

The Newest Market Insights

Browse by Sector

About Us

Terms & Privacy